Reply to diagnostic wk 4

 Please write a 300 word reply to my classmate, her discussion post is below. APA format. NO AI. My professor is a stickler for AI. PLEASE NO AI. scholarly written, APA formatted and a minimum of 3 references (which may include the course textbook). 

 

"Rheumatoid Arthritis

The patient's presentation strongly suggests rheumatoid arthritis (RA) as the most immediate diagnostic conclusion. Some key features supporting this as the working diagnosis include symmetrical involvement of the small joints (hands/wrists) with prolonged morning stiffness, as well as constitutional symptoms such as fatigue and malaise. As noted by Peterson et al. (2024), RA commonly manifests with symmetrical joint swelling and prolonged morning stiffness, which aligns closely with this patient’s symptoms. The progression from intermittent episodes to more persistent joint involvement further supports an evolving inflammatory process consistent with RA.

The differential diagnosis also encompasses lupus, psoriatic arthritis, osteoarthritis (OA), viral arthritis, reactive arthritis, and fibromyalgia. Lupus can present similarly with polyarthritis; however, other systemic symptoms are also typically present, such as rash or hematologic abnormalities. Given the symmetrical joint involvement in this patient, psoriatic arthritis is unlikely but can be ruled out with additional questions about skin and nail changes. The possibility of OA is less given this patient’s age and prolonged morning stiffness, as OA typically involves joint stiffness lasting less than 30 minutes upon awakening. Patients with viral arthritis (e.g., parvovirus) can have symptoms like those of RA, but it usually resolves on its own. Reactive arthritis can present with similar symptoms to RA but typically lasts a few months. Considering fibromyalgia as the source of fatigue is plausible, but the absence of objective joint swelling means inflammation isn't evident.

Diagnostic testing at this time should include bloodwork to confirm inflammation and order imaging to assess joints. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) tests can be ordered; anti-CCP antibodies are more specific and can help confirm/rule out rheumatoid arthritis. Sahin et al. (2025) state that anti-CCP antibodies are highly specific and predictive of disease progression. This antibody can be present for many years before disease onset, making it useful for diagnosing patients in the early stages of RA. Blood tests that can be done to confirm inflammation include erythrocyte sedimentation rate (ESR) and C- reactive protein (CRP).

Additionally, a complete blood count (CBC) can be performed to evaluate for anemia of chronic disease (Peterson et al., 2024). X-ray imaging of affected joints can be used to visualize joint space narrowing or erosions; however, rheumatoid arthritis can appear normal in early disease. If suspicion for inflammatory arthritis remains high, ultrasound or MRI can be used to visualize early synovitis changes (Peterson et al., 2024). These patients benefit from early treatment to prevent long-term complications such as joint deformities and damage. While NSAIDs and short-course glucocorticoids can be started for symptom control and decreasing inflammation, disease-modifying antirheumatic drugs (DMARDs) should be initiated as soon as possible. Methotrexate is typically used as first-line therapy and has been shown to decrease progression of joint damage and pain if started early in the disease. Faison et al. (2024) state RA requires treatment with DMARDs to slow progression of disease and prevent joint damage. Brown et al. (2024) also state, since its discovery, therapeutic intervention in RA has improved patient outcomes. The development of DMARDs has helped transform the disease.

References

Faison, M. N., Davis, A. M., & Trotter, K. C. (2024). Disease-Modifying Drugs for Adult-Onset Rheumatoid Arthritis. JAMA, 331(12), 1055–1056. https://doi.org/10.1001/jama.2023.26504

Peterson, E., Gallagher, M. K., & Wilbur, J. (2024). Rheumatoid Arthritis: Diagnosis and Management for the Family Physician. American Family Physician, 110(5), 515–526.  

Sahin, D., Di Matteo, A., & Emery, P. (2025). Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: A comprehensive review. Annals of Clinical Biochemistry, 62(1), 3–21. https://doi.org/10.1177/00045632241285843

Brown, P., Pratt, A. G., & Hyrich, K. L. (2024). Therapeutic advances in rheumatoid arthritis. BMJ (Clinical Research Ed.), 384, e070856. https://doi.org/10.1136/bmj-2022-070856"